{"prompt": "['OSTPDL1', 'Page 51 of 60', 'Note: If tumor markers are initially above the upper normal limit, they', 'must normalize for a patient to be considered in complete clinical', 'response.', 'Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or', 'maintenance of tumor marker level above the normal limits', 'Progressive disease (PD): Appearance of one or more new lesions and/or', 'unequivocal progression of existing non-target lesions. Unequivocal', 'progression should not normally trump target lesion status. It must be', 'representative of overall disease status change, not a single lesion', 'increase.', 'Overall best response assessment: Each patient will be classified', 'according to his \"best response\" for the purposes of analysis of treatment', 'effect. Best response is determined as outlined in Section 9.4 from a', 'sequence of overall response assessments.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 52 of 60', '9.3', 'Response Criteria for Evaluable Disease', 'Note: all participants must have measurable disease, but they can also', 'have evaluable disease in addition to measurable disease.', 'Evaluable disease: The presence of at least one lesion, with no lesion that', 'can be accurately measured in at least one dimension. Such lesions may', 'be evaluable by nuclear medicine techniques, immunocytochemistry', 'techniques, tumor markers or other reliable measures.', 'Complete response (CR): Disappearance of all evaluable disease.', 'Partial response (PR): Partial responses cannot be determined in patients', 'with evaluable disease.', 'Stable disease (SD): That which does not qualify as Complete Response', '(CR), Partial Response (PR), or Progressive Disease.', 'Progressive disease (PD): The appearance of one or more new lesions or', 'evidence of laboratory, clinical, or radiographic progression.', 'Overall best response assessment: Each patient will be classified', 'according to his \"best response\" for the purposes of analysis of treatment', 'effect. Best response is determined as outlined in Section 9.4 from a', 'sequence of overall response assessments.', '9.4', 'Best Response', '9.4.1 Evaluation of Best Overall Response', 'The best overall response is the best response recorded from the start of', 'the treatment until disease progression/recurrence (taking as reference', 'for progressive disease the smallest measurements recorded since the', \"treatment started). The patient's best response assignment will depend\", 'on the achievement of both measurement and confirmation criteria.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 53 of 60', 'Table 1: Patients with Measurable Disease (i.e., Target Disease)', 'Non-Target', 'Overall', 'Target Lesions', 'New Lesions', 'Lesions', 'Response', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/Non-PD', 'No', 'PR', 'CR', 'Not evaluated', 'No', 'PR', 'PR', 'Non-CR/Non-', 'No', 'PR', 'PD/not', 'evaluated', 'SD', 'Non-CR/Non-', 'No', 'SD', 'PD/not', 'evaluated', 'PD', 'Any', 'Yes or No', 'PD', 'Any', 'PD*', 'Yes or No', 'PD', 'Any', 'Any', 'Yes', 'PD', '* In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as', 'disease progression.', 'Note: Patients with a global deterioration of health status requiring discontinuation of treatment', 'without any objective evidence of disease progression at that time should be reported as', '\"symptomatic deterioration.\" Every effort should be made to document the objective progression', 'even after discontinuation of treatment.', 'Table 2: Patients with Non-Measurable Disease (i.e., Non-Target Disease)', 'Non-Target Lesions', 'New Lesions', 'Overall Response', 'CR', 'No', 'CR', 'Non-CR/Non-PD', 'No', 'Non-CR/Non-PD*', 'Not all evaluated', 'No', 'Not evaluated', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', '\"non-CR/non-PD\" is preferred over \"stable disease\" for non-target disease since SD is', 'increasingly used as an endpoint for assessment of efficacy in some trials so to assign this', 'category when no lesions can be measured is not advised.', 'Table 3: Sequences of overall response assessments with corresponding', 'best response', '1st Assessment', '2nd Assessment', 'Best Response', 'Progression', 'Progressive disease', 'Stable, PR, CR', 'Progression', 'Progressive disease', 'Stable', 'Stable', 'Stable', 'Stable', 'PR, CR', 'Stable', 'Stable', 'Not done', 'Not RECIST classifiable', 'PR', 'PR', 'PR', 'PR', 'CR', 'PR', 'PR, CR', 'Not done', 'Not RECIST classifiable', 'CR', 'CR', 'CR', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}